Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.52
22.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Income from Continuing Operations
Shanghai Pharmaceuticals Holding Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Income from Continuing Operations
¥5.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Income from Continuing Operations
¥14B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Income from Continuing Operations
¥2.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Income from Continuing Operations
¥2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Income from Continuing Operations
¥3.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Income from Continuing Operations
¥1.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a key player in China's healthcare sector, emerged from its roots in the early 1990s to become one of the largest pharmaceutical companies in the country. It operates in two main segments: pharmaceutical manufacturing and distribution. With a strong portfolio of generic and branded medications, the company leverages its extensive distribution network to reach hospitals and pharmacies across China. Shanghai Pharmaceuticals focuses on innovative drug development and has made significant strides in research, particularly in oncology and high-demand therapeutic areas, positioning itself well for growth in a rapidly evolving market. For investors, Shanghai Pharmaceuticals represents a compelling opportunity, not only due to its robust domestic market but also its potential for international expansion. The company's commitment to R&D, alongside strategic partnerships with global pharmaceutical firms, underscores its forward-thinking approach. Additionally, as China's healthcare reforms push for improved access to medicines, Shanghai Pharmaceuticals stands to benefit from increased demand. With a seasoned management team and a solid track record of consistent revenue growth, investors looking for exposure in the burgeoning Asian pharmaceutical landscape may find Shanghai Pharmaceuticals an attractive addition to their portfolios.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.2B
CNY
Based on the financial report for Sep 30, 2024, Shanghai Pharmaceuticals Holding Co Ltd's Income from Continuing Operations amounts to 5.2B CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
6%
Over the last year, the Income from Continuing Operations growth was -12%. The average annual Income from Continuing Operations growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been -7% over the past three years , 3% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
